Appendix 4D
Half-Year Financial Report

Name of entity:
ACTINOGEN MEDICAL LIMITED

ABN or equivalent company reference:
14 086 778 476

Current Period:
1 July 2023 to 31 December 2023
(Previous corresponding period: 1 July 2022 to 31 December 2022)

RESULTS FOR ANNOUNCEMENT TO THE MARKET

	31/12/2023 $	31/12/2022 $	Change $	Amount change $
Revenue from ordinary activities	106,774	135,912	-21%	(29,138)
Loss from ordinary activities after tax attributable to members	11,556,659	7,438,708	55%	(4,117,951)
Net loss for the period attributable to members	11,556,659	7,438,708	55%	(4,117,951)
Net tangible asset per share	0.004	0.007		

BRIEF EXPLANATION OF THE ABOVE FIGURES
Revenues from ordinary activities relates to interest revenue from cash held in interest-bearing accounts and short-term deposits.

The total net loss after tax increased due primarily to an increase in Research & Development expenditure. Refer to the attached Directors' Report and financial statements for further information.

Details of entities over which control has been gained or lost during the period
Not applicable. There has been no entity over which control has been gained or lost during the period.

Dividend / Distribution Payments or Reinvestment Plans
Not applicable. No dividends have been paid or declared during the half year ended 31 December 2023, in the previous financial year ended 30 June 2023 or in the previous corresponding period. The Company does not propose to pay dividends in the immediate future.

Associates / Joint Ventures
Not applicable. The Company has not engaged in the acquisition of associates nor has it engaged in any joint ventures in the half year ended 31 December 2023.

Foreign Entities
Not applicable.

Review Conclusion
This Report is based on the Interim Financial Report for the half year ended 31 December 2023. The financial report has been subject to a review by an independent auditor and the review is not subject to qualification.

Steven J Gourlay

Dr Steven Gourlay
Managing Director
26 February 2024
Sydney, New South Wales

Actinogen

Interim Financial Report

31 December 2023

Contents

Disclaimer

This Interim Report may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realis

Operating & Financial Review

1. PRINCIPAL ACTIVITIES

The principal activity of the Company during the half year focused on the ongoing development of Xanamem,® a unique inhibitor of the 11β- HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Brain cortisol is associated with a number of neurological diseases, including neurodegenerative disease such as Alzheimer's Disease (AD), neuropsychiatric diseases such as Major Depressive Disorder (MDD or Depression), and Fragile X Syndrome (FXS).

2. OPERATIONS REVIEW

Highlights - Continuing to *Follow the Science*:

Received approval of application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease

Advancing two major Phase 2 clinical trial programs:

- **Enrolment continues to track well in the six-week XanaCIDD Phase 2a Depression clinical trial at Australian and UK sites, which now exceeds 75% of the planned 160 trial participants. Results are expected in Q2CY024**
- **Trial site activation and participant screening has commenced in the XanaMIA Phase 2b Alzheimer's Disease trial. Treatment of the first of 100 participants at Australian sites is expected to begin shortly. Final results are expected in H2CY2025 with an interim analysis due in H1CY2025.**

Received a $4.8 million[1] Research & Development (R&D) tax incentive rebate

Completed the development of an improved synthetic process of Xanamem drug substance and manufacture of a 1kg demonstration batch as a prelude to larger scale manufacture

Published Xanamem human brain PET study in peer-reviewed journal, The Journal of Alzheimer's Disease

Initiated strategic changes and additions to the executive and operational teams:

- **Appointed new full time Chief Financial Officer and conducted limited reorganization of Clinical Operations team to align with upcoming business requirements**
- **Continued to fill strategic operational roles to ensure the success of its clinical development program, including those required for the XanaMIA Phase 2b Alzheimer's disease trial in Australia.**

Presented at numerous international and Australian AD, investment and partnering meetings

Completed a successful $10 million capital raising in September.

The first half of the Company's 2024 financial year was marked by clinical pipeline progress and several major milestones and events:

Approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of an application for an Innovation Passport as part of the ILAP for Xanamem in the treatment of Alzheimer's disease

- **Represents an independent endorsement by an international regulator of the potential impact of the Xanamem program**
- **Key benefits of this approval include:**
    - Entry point to the ILAP which aims to accelerate time to market
    - Linkage to a portfolio of activities through the product-specific creation of the Target Development Profile (TDP) in conjunction with the MHRA
    - Opportunities for enhanced regulatory and other stakeholder input including from partner agencies such as the MHRA and National Institute for Health and Care Excellence (NICE).

Advancing Phase 2 trial programs:

- **XanaCIDD Phase 2a depression clinical trial:**
    - Enrolment continues in the XanaCIDD Phase 2a trial in 160 patients with cognitive impairment associated with persistent major depressive disorder (MDD). Treatment is with either 10mg Xanamem or placebo, daily over six weeks
    - The full complement of clinical sites is open in Australia and the UK which are actively recruiting, enrolling and treating patients, with enrolment now exceeds 75% (>120 of 160 planned participants)
    - Results are anticipated in Q2 CY2024.

® Xanamem is a registered trademark of Actinogen Medical Limited
[1] All financial data is in Australian dollars unless stated otherwise

- **XanaMIA Phase 2b Alzheimer's disease clinical trial:**
    - The first Australian investigational sites have been activated for the XanaMIA Phase 2b clinical trial of Xanamem enrolling 220 patients with mild to moderate Alzheimer's disease (AD)
    - Sites have begun to recruit patients for screening with an elevated blood pTau biomarker (the same biomarker used to select patients shown to have a large Xanamem clinical benefit in the previous Phase 2a biomarker trial)
    - Treatment, which is expected to begin imminently, will be with either 10mg Xanamem or placebo daily over 36 weeks
    - Enrolment of the first 100 patients will take place at Australian sites, and an administrative interim analysis will occur when approximately 100 patients reach 24 weeks of treatment (interim results expected H1 CY2025)
    - Final results are anticipated in H2 CY2025.

$4.8 million R&D tax incentive rebate:

- In November, the Company announced that it had received an R&D tax incentive rebate of $4.8 million from the Australian Tax Office for the 2023 financial year
- The R&D tax incentive is an Australian federal government program under which companies receive cash refunds for eligible research and development expenditure.

Manufacturing:

- The Company's new contract manufacturer, Asymchem, has completed the development of an improved synthetic process of Xanamem drug substance and completed the manufacture of a 1kg demonstration batch as a prelude to larger scale manufacture.

Xanamem human brain PET study published in peer-reviewed journal, *The Journal of Alzheimer's Disease*

- This study was published on 19 January 2024 and can be accessed by the following link: https://pubmed.ncbi.nlm.nih.gov/38250767/

  The study concluded that:
  1) Xanamem achieved high target occupancy of 66-85%, which exceeded the 30-60% inhibition required for effectiveness in animal models
  2) A dose level of 10 mg daily achieved near saturation of the enzyme target, meaning that higher doses achieved little additional occupancy
  3) The study results support exploring doses of ≤10 mg in clinical trials, consistent with the Company's ongoing phase 2 trials.

Executive and clinical operations teams:

- In November, the Company appointed Mr Will Souter as a new full time Chief Financial Officer. Mr Souter commenced in the role on 5 February 2024
- The Company also initiated a limited reorganisation which resulted in the position of Senior Vice President, Product Development being made redundant. Ms Cheryl Townsend, Vice President Clinical Operations, now reports directly to the CEO
- The Company continues to fill strategic operational roles to ensure the success of its clinical development program, including those required for the XanaMIA Phase 2b Alzheimer's disease trial in Australia.

Neuroscience webinar for investors:

- Following the Science is fundamental to all of Actinogen's activities and is the foundation for the Company's ongoing Clinical Trials Science Forum (CTSF) series of plain English educational webinars
- On 31 August, leading neuroscience and cognition expert Professor Paul Maruff joined Actinogen's Chief Medical Officer Dr Dana Hilt to discuss recent progress in the AD clinical development field and cognitive impairment associated with depressive disorder
- This highly informative discussion and Q&A session focused on interpreting the various testing methods that have been applied to cognition in AD and cognitive impairment associated with depressive disorder (CIDD) and used to evaluate the efficacy of new drugs such as Xanamem
- Xanamem works on lowering brain tissue cortisol and is one of only a few development programs that has demonstrated clinical activity on cognition in multiple placebo-controlled trials.

CEO and CMO presented at numerous significant international conferences and conducted meetings at industry gatherings to continue evaluating potential value-add regional and global business development opportunities, including:

- The Alzheimer's Association International Conference (AAIC) in Amsterdam, The Netherlands on 17-20 July. CMO Dr Dana Hilt presented an academic poster which summarized data from three earlier Phase 1 and 2a Xanamem trials and concluded that Xanamem displays activity in multiple domains of cognition, and that treatment with Xanamem results in clinically meaningful slowing of disease
- The 2023 Bioshares Biotech Summit in Hobart on 25 July, which brought together biotech companies and investors for company presentations, industry engagement and investor meetings. Dr Gourlay's presentation summarized the Xanamem story and near-term Phase 2 clinical and regulatory milestones
- The Dementia Trials Australia Annual Scientific Meeting in Sydney, Australia on 6 October where the theme was: The new era in AD therapies. ACW CEO Dr Steven Gourlay provided a presentation titled Targeted modification of brain cortisol – a novel, nonamyloid approach
- The 17th international congress of the Asian Society Against Dementia (ASAD) in Bandung, Indonesia on 29 September where ACW Clinical Scientist Dr Jack Taylor presented to an audience comprising neurologists, psychiatrists, geriatricians, and other experts from local, national and world-class institutions focused on accelerating scientific discoveries in cognitive impairment, dementia and Alzheimer's disease. The Company congratulates Dr Taylor who received the congress prize for Best Young Research Oral Presentation
- The BIO Investor Forum in San Francisco, USA on 18 October, where CEO Dr Steven Gourlay conducted investor and industry meetings
- The 16th annual CTAD conference in Boston, USA on 25 October where CMO Dr Dana Hilt presented an academic poster that provided an

overview of the Xanamem therapeutic rationale, the positive results of two prior placebo-controlled trials in healthy volunteers demonstrating pro-cognitive effects, and a biomarker trial in patients with mild Alzheimer's disease that showed cognitive and clinical benefit. CEO Dr Steven Gourlay also attended the conference and was joined by Dr Hilt in key external meetings with other Biotech/Pharma companies and investors

- Post balance date on 7 January 2024, CMO Dr Dana Hilt presented to the Sachs Associates 7th Annual Neuroscience Innovation Forum in San Francisco, USA. Dr Hilt recapped the strong scientific rationale for modification of brain tissue cortisol levels with Xanamem, presented the clinical benefits seen in multiple trials to date and outlined the design of the two on-going Phase 2 trials, with near-term major results in Depression and Alzheimer's disease in 2024 and 2025 respectively
- Immediately following the Sachs Forum, CEO Dr Steven Gourlay and CMO Dr Hilt participated in a significant number of partnering, analyst and investor meetings associated with the 42nd Annual J.P. Morgan Healthcare Conference from 8 to 12 January.

Capital raising:

- On 7 September, the Company announced the successful completion of a $10 million non-renounceable rights issue offer to existing shareholders. All shares on offer were taken up by existing shareholders and through shortfall commitments from existing and new shareholders
- Funds raised by the rights issue have been applied to progressing the Company's Phase 2 clinical trial program including the completion of the XanaCIDD trial in patients with cognitive impairment associated with depression, startup costs associated with the XanaMIA trial in patients with mild to moderate Alzheimer's disease, and general working capital.

For further information on all the above events, please refer to the ASX announcements section under the Investor Centre tab on the Actinogen website.

3. FINANCIAL REVIEW

(a) Financial Performance

The financial performance of the Company during the half year ended 31 December 2023 is as follows:

	Half year ended 31/12/2023	Half year ended 31/12/2022
Revenue and other income ($)	1,015,804	1,140,013
Net loss after tax ($)	(11,556,659)	(7,438,708)
Loss per share (cents)	(0.56)	(0.41)
Dividend ($)	-	-

(b) Financial Position

The financial position of the Company as at 31 December 2023 is as follows:

	As at 31/12/2023 $	As at 30/06/2023 $
Cash and cash equivalents	11,472,389	8,460,074
Net assets / Total equity	11,978,440	13,407,215
Contributed equity	90,783,121	78,712,128
Accumulated losses	(80, 248,212)	(68,691,553)

4. MATERIAL RISKS

In addition to risks associated with any business there are specific, material risks that, either individually or in combination, may materially and adversely affect the future operating and financial performance and prospects of Actinogen and the value of its shares. Some of these risks may be mitigated by Actinogen's internal controls and processes but some are outside the control of Actinogen, its directors and management. The material risks identified by management are described below:

Risk	Implication	Mitigation
Research and Development Activities	Actinogen's future success is dependent on the performance of Actinogen's lead molecule, Xanamem®, in clinical trials and whether it proves to be a safe and effective treatment. Xanamem is an experimental product in Phase 2 clinical development. Product commercialization resulting in potential product sales revenues are likely to be years away without any guarantee that it will be successful. It requires additional research and development, including ongoing clinical evaluation of safety and efficacy in clinical trials and regulatory approval prior to marketing authorization. Until Actinogen is able to provide further clinical evidence of the ability of Xanamem to improve outcomes in patients, the future success of its technology remains speculative. Research and development risks include uncertainty of the outcome of results, difficulties or delays in development and generally the uncertainty that surrounds the scientific development of pharmaceutical products.	Mitigation measures include 'following the science' of the data generated for Xanamem to date, hiring expert clinical development professionals to design, oversee and analyse the trial program, engagement of leading contract research organisations to manage components of the trials and drive recruitment as well as engagement of well-qualified clinical sites experienced in clinical trial execution and in the relevant therapeutic areas.
Regulatory Approvals	Actinogen operates within a highly regulated industry, relating to the manufacture, distribution and supply of pharmaceutical products. There is no guarantee that Actinogen will obtain the required approvals, licenses and registrations from relevant regulatory authorities in jurisdictions in which it operates. The commencement of clinical trials may be delayed and Actinogen may incur further costs if the Food and Drug Administration (FDA) and other regulatory agencies are tardy or observe deficiencies that require resolution or request additional studies be conducted in addition to those that are currently planned. A change in regulation may also adversely affect Actinogen's ability to commercialize and manufacture its treatments.	Mitigation measures include operating under a US FDA Investigational New Drug (IND) process, engagement of suitably qualified and experienced persons with expertise in the regulation of small molecule therapies, establishing relationships with regulators to facilitate feedback and guidance from them, regular review of evolving regulatory requirements and analysis of the Company's activities and plans against regulatory expectations in key jurisdictions, and ensuring that the expectations and uncertainties related to regulatory approvals, and the timing of such approvals, are included in business plans.
Intellectual Property	Securing rights in technology and patents is an integral part of securing potential product value in the outcomes of biotechnology research and development. Competition in retaining and sustaining protection of technology and the complex nature of technologies can lead to patent disputes. Actinogen's success depends, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. Because the patent position of biotechnology companies can be highly uncertain and frequently involves complex legal and factual questions, neither the breadth of claims allowed in biotechnology patents nor their enforceability can be predicted. There can be no assurance that any patents which Actinogen may own, access or control will afford Actinogen commercially significant protection of its technology or its products or have commercial application or that access to these patents will mean that Actinogen will be free to commercialise its technology. Competitors may file patents which could limit the Company's freedom to operate for its technologies. The granting of a patent does not guarantee that the rights of others are not infringed or that competitors will not develop technology or products to avoid Actinogen's patented	Mitigation measures include use of expert patent attorneys, regular review of the relevant patent landscape, filing of additional patents and maintenance of patents in a broad geography covering major pharmaceutical markets.

Risk	Implication	Mitigation
	technology. Actinogen's current patenting strategies do not cover all countries which may lead to generic competition arising in those markets.	
Partnership Model	While undertaking its Phase 2 clinical program the Company is actively pursuing value-add partnership(s) to expand the trial program further and secure commercialization pathways in one or more territories. This model, which typically involves entering into commercial arrangements with other companies by which Actinogen would license its Xanamem technology to the partner in one or more indications and/or geographies and the partner assumes some or all responsibility for progressing, and paying for, the clinical trials and eventual commercialization. This strategy involves the risk that the Company will lose some or all control of the development timetable of its products to its commercial partner(s), which may give rise to an unanticipated delay in any commercial returns. Further, the Company may be unable to enter into arrangements with suitable commercial partners in respect of relevant indications. If either of these outcomes occurred, the Company's business and operations may be adversely affected.	Mitigation measures employed by the Company include: using expert business development professionals to build relationships with potential partners, performing rigorous due diligence, ensuring that the commercial terms negotiated are fair and utilising expert legal advice to ensure that appropriate warranties and commitments are included in contracts, and that the contracts reflect the agreed commercial position. The Company seeks to form partnerships with relevant regulatory agencies including the FDA, EMA, and MHRA. This was most recently evidenced by the grant of a UK Innovation Passport.
Manufacturing	The Company's products are manufactured using a specialised manufacturing process at an expert third party facility, as is the norm in our industry. An inability of these third party contract manufacturing organisations to continue to manufacture the Company's products in a timely, economical and/or consistent manner, including any scale up of manufacturing processes, or to maintain legally compliant manufacturing to maintain product supply, could adversely impact on the progress of the Company's development programs and potentially on the financial performance of the Company.	Mitigation measures include performing rigorous due diligence on contract manufacturers, engaging contract manufacturers with strong track records and sufficient capability to meet the Company's foreseeable needs, employing senior managers responsible for managing and monitoring the performance of contract manufacturers, and maintenance of quality systems and related documentation.
Fundraising risk	Actinogen is reliant upon fundraising to fund its operations. Funds may be available in the future from grants, development and commercial partnerships, tax incentives and capital markets but are not guaranteed. Capital market volatility has affected many companies since 2020 and future volatility may impact Actinogen's ability to raise future funds.	Mitigation measures include filing of multiple grant applications, key management focus on partnership relationships, use of specialist advisors in tax, business development and investor relations, maintaining high quality analyst coverage, frequent communications to retail and institutional investors and having a presence at many scientific and business conferences.

5. BUSINESS STRATEGY AND OUTLOOK

Actinogen's strategic priorities continue to focus on three key elements:

- **Accelerate clinical development in cognitive impairment**
- **Forward planning**
- **Create value from partnerships.**

Accelerate clinical development in cognitive impairment

The Phase 2a clinical biomarker trial highlighted the benefits of Xanamem in biomarker-positive patients. These results strongly support the feasibility of using both cognitive testing and the CDR-SB endpoint for our Phase 2b trial. Using these data to simulate and design the Phase 2b trial should significantly increase its chances of success.

Our key goals under this strategic priority are:

- Build on improved attention and working memory in two independent, placebo-controlled trials
- Complete Phase 2a trial now underway in patients with Cognitive Impairment and Depressive Disorder (XanaCIDD)
- Build on the large Xanamem effect seen in patients with mild AD and elevated pTau181 protein in the blood (an indication of progressive AD)
- Initiate Phase 2b trial in patients with the early stages of Alzheimer's disease and elevated pTau (XanaMIA Part B)
- Leverage 'hands on' clinical operations and management based in Australia to speed timelines and reduce cost.

Forward planning

In addition to conducting high quality clinical trials there are numerous other important activities for successful drug development. At Actinogen, we proactively plan and manage all aspects of the Xanamem development plan.

Our key goals under this strategic priority are:

- Complete additional manufacturing batch for scale-up and supply of future clinical trials
- Use to-be-marketed tablet formulation in all future trials
- Integrate global regulatory strategic planning to optimize path to marketing approvals
- Plan and conduct required regulatory nonclinical studies to the Good Laboratory Practice standard
- Plan and conduct ancillary clinical pharmacology studies required for marketing approvals.

Create value from partnerships

Our active business development plan maintains and develops relationships with all potential drug development partners, both large and small, regional and global. The Company also seeks to form partnerships with relevant regulatory agencies including the FDA, MHRA and EMA, an example of which is the recent grant of a UK Innovation Passport. We continue to see a high level of interest in our programs.

Strengthened by the addition of Dr Dana Hilt to the team, we attended in person at an increased number of important international conferences during the year to facilitate relationship building, partner engagement, and Actinogen's presence as a Phase 2 clinical-stage company.

We use our Alzheimer's program as the 'core' collaboration with the US FDA covering manufacturing, quality and nonclinical matters. We also aim to build and maintain good working relationships with other global regulators such as the European Medicines Agency (EMEA) and the UK Medicines and Healthcare products Regulatory Agency.

Our key goals under this strategic priority are:

- Prioritize high value regional partnerships in the near term
- Engage with the universe of potential biopharma partners who could create synergy for the Xanamem program
- Maintain close working relationships with key regulators such as the US FDA, UK MHRA and the EMA
- Partner with leading clinical trial implementation providers
- Partner with key community organizations in Australia and globally.

Our FY2024 strategic priorities were also summarized in an infographic on page 11 of the 2023 annual report and on the Company's website www.actinogen.com.au.

Outlook

The Company remains confident about its prospects in FY2024 and beyond. Actinogen continues with the XanaCIDD trial that will report results in the second quarter of 2024, using a primary endpoint measuring cognition that was validated by demonstrating Xanamem benefits in two prior volunteer trials. Xanamem effects on depression itself will also be measured.

The second major clinical milestone is the interim analysis of the XanaMIA Phase 2b trial in patients with AD, expected in H1 CY2025. To have two major clinical readouts in the next 18 months reflects the successful hard work and dedication of the Actinogen team.

Meanwhile manufacturing, regulatory, clinical pharmacology and nonclinical planning and activities continue in high order to enable rapid expansion on successful Phase 2 results.

We are committed to proactive management of all aspects of our business to ensure the best possible outcomes for shareholders. This includes our current clinical trials program, our forward planning for future trials and eventual drug commercialization, and working closely with existing and potential new partners.

Directors' Report

Your Directors present their report pertaining to Actinogen Medical Limited ('Actinogen Medical' or 'the Company') for the half year ended 31 December 2023.

1. BOARD OF DIRECTORS

The names and details of the Company's Directors in office during the financial year and until the date of this Report are as follows. Directors were in office for the entire period, unless otherwise stated.

Name	Position	Appointed	Resigned
Dr Geoffrey Brooke	Non-Executive Chairman	1/03/2017	Current
Dr Steven Gourlay	Managing Director / Chief Executive Officer	24/03/2021	Current
Dr George Morstyn	Non-Executive Director	1/12/2017	Current
Mr Malcolm McComas	Non-Executive Director	4/04/2019	Current
Dr Nicki Vasquez	Non-Executive Director	1/03/2023	Current

2. OPERATING AND FINANCIAL REVIEW

Please refer to pages 3 to 8 of this interim report for information on the Company's principal activities and operating review.

3. AUDITOR'S INDEPENDENCE DECLARATION

The Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 for the half year ended 31 December 2023 forms a part of the Directors' Report and can be found on page 10. Signed in accordance with a resolution of the Board of Directors.

Steven J Gourlay

Dr Steven Gourlay
Managing Director
Sydney, New South Wales
26 February 2024

Ernst & Young
11 Mounts Bay Road
Perth WA 6000 Australia
GPO Box M939 Perth WA 6843

Tel: +61 8 9429 2222
Fax: +61 8 9429 2436
ey.com/au

Building a better working world

Auditor's independence declaration to the directors of Actinogen Medical Limited

As lead auditor for the review of the half-year financial report of Actinogen Medical Limited for the half-year ended 31 December 2023, I declare to the best of my knowledge and belief, there have been:

a. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review;

b. No contraventions of any applicable code of professional conduct in relation to the review; and

c. No non-audit services provided that contravene any applicable code of professional conduct in relation to the review.

Ernst & Young

Timothy Dachs
Partner
26 February 2024

Statement of Comprehensive Income

For the half year ended 31 December 2023

	Note	Half year ended 31/12/2023 $	Half year ended 31/12/2022 $
Interest revenue		106,774	135,912
Other income		909,030	1,004,101
Total revenue & other income	5	**1,015,804**	1,140,013
Research & development costs	5	(8,952,776)	(5,384,406)
Employment costs		(1,909,240)	(1,295,899)
Corporate & administration costs		(907,903)	(734,739)
Finance costs		(11,115)	(10,061)
Realised (loss) / unrealised gain on foreign currency		805	(83,786)
Share-based payment expenses		(580,266)	(868,775)
Amortisation expense	10	(157,658)	(156,373)
Depreciation expense (right-of-use asset)	9	(40,504)	(40,504)
Depreciation expense (office equipment)	8	(13,806)	(4,178)
Total expenses		**(12,572,463)**	(8,578,721)
Loss before income tax		**(11,556,659)**	(7,438,708)
Income tax expense		-	-
Loss for the year		**(11,556,659)**	(7,438,708)
Other comprehensive income			
Items that may be reclassified subsequently to profit and loss:			
Other comprehensive income		-	-
Total comprehensive loss for the year		**(11,556,659)**	(7,438,708)
Loss per share for attributable to the ordinary equity holders of the Company			
Basic and diluted loss per share in cents		**(0.56)**	(0.41)

The above Statement of Comprehensive Income should be read in conjunction with the accompanying Notes.

Statement of Financial Position

As at 31 December 2023

	Note	As at 31/12/2023 $	As at 30/06/2023 $
Current Assets			
Cash and cash equivalents	6	11,472,389	8,460,074
Other receivables and prepayments	7	382,098	4,228,311
Total Current Assets		11,854,487	12,688,385
Non-Current Assets			
Property, plant and equipment	8	24,970	37,276
Intangible assets	10	2,250,054	2,407,712
Right-of-use assets	9	34,929	75,432
Total Non-Current Assets		2,309,953	2,520,420
TOTAL ASSETS		**14,164,440**	15,208,805
Current Liabilities			
Trade and other payables	11	2,033,458	1,559,470
Provision for employee entitlements		107,913	155,187
Lease liability	9(b)	44,629	86,933
Total Current Liabilities		2,186,000	1,801,590
Non-Current Liabilities			
Lease liability	9(b)	-	-
Total Non-Current Liabilities		-	-
TOTAL LIABILITIES		**2,186,000**	1,801,590
NET ASSETS		**11,978,440**	13,407,215
Equity			
Contributed equity	12(a)	90,783,121	78,712,128
Reserve shares	12(b)	(9,721,367)	(7,197,992)
Reserves	13	11,164,898	10,584,632
Accumulated losses		(80,248,212)	(68,691,553)
TOTAL EQUITY		**11,978,440**	13,407,215

The above Statement of Financial Position should be read in conjunction with the accompanying Notes.

Statement in Changes of Equity

For the half year ended as at 31 December 2023

Half year ended 31 December 2023	Contributed Equity $	Accumulated Losses $	Option Reserve $	Reserve Shares $	Total $
Balance as at 1 July 2023	78,712,128	(68,691,553)	10,584,632	(7,197,992)	13,407,215
Loss for the half year	-	(11,556,659)	-	-	(11,556,659)
Other comprehensive income	-	-	-	-	-
Total comprehensive loss for the half year	-	(11,556,659)	-	-	(11,556,659)
Transactions with equity holders in their capacity as equity holders:					
Shares issued during the half year	12,524,824	-	-	(2,523,375)	10,001,449
Capital raising costs	(453,831)	-	-	-	(453,831)
Share-based payments	-	-	580,266	-	580,266
Balance as at 31 December 2023	**90,783,121**	**(80,248,212)**	**11,164,898**	**(9,721,367)**	**11,978,440**

Half year ended 31 December 2022	Contributed Equity $	Accumulated Losses $	Option Reserve $	Reserve Shares $	Total $
Balance as at 1 July 2022	76,942,670	(57,939,283)	9,067,982	(6,331,492)	21,739,877
Loss for the half year	-	(7,438,708)	-	-	(7,438,708)
Other comprehensive income	-	-	-	-	-
Total comprehensive loss for the half year	-	(7,438,708)	-	-	(7,438,708)
Transactions with equity holders in their capacity as equity holders:					
Shares issued during the half year	919,458	-	-	(16,500)	902,958
Capital raising costs	-	-	-	-	-
Share-based payments	-	-	868,775	-	868,775
Balance as at 31 December 2022	77,862,128	(65,377,991)	9,936,757	(6,347,992)	16,072,902

The above Statement of Changes in Equity should be read in conjunction with the accompanying Notes.

Statement of Cash Flows

For the half year ended 31 December 2023

	Note	Half year ended 31/12/2023 $	Half year ended 31/12/2022 $
Cash Flows from Operating Activities			
Interest received		106,774	135,912
Interest paid		(10,569)	(10,061)
Payments to suppliers and employees		(3,181,624)	(2,135,892)
Payments for research and development		(8,198,944)	(4,813,187)
Government R&D tax rebate and grants received		4,792,865	4,165,402
Net cash outflow from operating activities		**(6,491,498)**	**(2,657,826)**
Cash Flows from Investing Activities			
Purchase of property, plant and equipment	8	(1,500)	(13,535)
Net cash outflow from investing activities		**(1,500)**	**(13,535)**
Cash Flows from Financing Activities			
Proceeds from issue of shares	12	10,001,449	902,958
Transaction costs associated with issue of shares	12	(453,831)	-
Principal repayment on leases	9(a)	(42,304)	(38,518)
Net cash inflow from financing activities		**9,505,313**	**864,440**
Net increase/(decrease) in cash and cash equivalents		3,012,315	(1,806,921)
Cash and cash equivalents at beginning of the half year		8,460,074	16,370,283
Effect of movement in exchange rates on cash held		-	(79,535)
Cash and cash equivalents at the end of the half year	6	**11,472,389**	**14,483,827**

The above Statement of Cash Flows should be read in conjunction with the accompanying Notes.

Notes to the Financial Statements

For the half year ended 31 December 2023

1. CORPORATE INFORMATION

The interim financial statements of Actinogen Medical Limited ("Actinogen Medical" or the "Company") for the half year ended 31 December 2023 were authorised in accordance with a resolution of Directors on 26 February 2024. Actinogen Medical is a for profit company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX). The nature of operations and principal activities of the Company are described in the Directors' Report. The registered office of the Company is located at Suite 901, Level 9, 109 Pitt Street, Sydney, NSW, Australia.

2. BASIS OF PREPARATION AND CHANGES TO THE COMPANY'S ACCOUNTING POLICIES

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated below. The financial statements of the Company are for the half year ended 31 December 2023.

(a) Basis of preparation

The interim condensed financial statements for the six months ended 31 December 2023 have been prepared in accordance with AASB 134 Interim Financial Reporting. The Company has prepared the financial statements on the basis that it will continue to operate as a going concern. The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual financial statements as at 30 June 2023.

(b) Going concern basis

This interim report has been prepared on the going concern basis which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business. During the half year ended 31 December 2023, the Company incurred a net loss after tax of $11,556,659 (2022: $7,438,708) and had net cash outflows from operating activities of $6,491,498 (2022: $2,657,826). With $11,472,389 cash at bank at 31 December 2023, the Company is well funded in the short-term to support ongoing research and development activities, including the completion of the XanaCIDD trial, as well as its corporate and administrative requirements. Further funding will be required to complete other ongoing research and development initiatives, including the XanaMIA Phase 2b AD trial. In the Directors' opinion, there are reasonable grounds to believe that the Company has the ability to raise further funding as and when required based on its past ability to raise equity funding. In forming this view the Directors have taken into consideration the following:

- The Company has $11,472,389 in cash and cash equivalents as at 31 December 2023
- The Company is listed on the ASX and therefore has access to the Australian equity capital markets
- The Company has the ability to modify its planned but not committed expenditure on Clinical Trial activities if required in order to continue as a going concern.

Nonetheless, if funds are not forthcoming and there is a need to reduce discretionary expenditure, there is uncertainty whether the Company will be able to progress with all of its current research and development initiatives and continue as a going concern and therefore, in this circumstance, whether it will be able to realise its assets and discharge its liabilities in the normal course of business at the amounts stated in the financial statements.

No adjustments have been made relating to the recoverability and classification of recorded asset amounts and the classification of liabilities that might be necessary should the Company not continue as a going concern.

(c) New standards, interpretations and amendments adopted by the Company

The accounting policies adopted in the preparation of the interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended 30 June 2023, except for the adoption of new standards effective as of 1 July 2023, which did not have a material impact on the Company. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

3. SEGMENT INFORMATION

The Company's sole operations are within the biotechnology industry within Australia. Given the nature of the Company, its size and current operations, the Company's management does not treat any part of the Company as a separate operating segment. Internal financial information used by the Company's decision makers is presented on a "whole of entity" manner without dissemination to any separately identifiable segments. Accordingly, the financial information reported elsewhere in this financial report is representative of the nature and financial effects of the business activities in which it engages and the economic environments in which it operates. All non-current assets are held in Australia and all income is derived in Australia.

Notes to the Financial Statements

4. FINANCIAL RISK MANAGEMENT

The Company's principal financial liabilities comprise trade, other payables and lease liabilities. The Company's principal financial assets include trade and other receivables, and cash and short-term deposits.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's Board and senior management oversees the management of these risks however, the Company's overall risk in these areas is not significant enough to warrant a formalised specific risk management program. Risk management is carried out in their day-to-day functions as the overseers of the business. Set out below is an overview of the financial instruments held by the Company as at 31 December 2023:

	Cash and cash equivalents $	Financial assets / liabilities at amortised cost $
As at 31 December 2023		
Financial assets		
Cash and cash equivalents	11,472,389	-
Other receivables and prepayments	-	156,385
Total current assets	11,472,389	156,385
Total financial assets	**11,472,389**	**156,385**
Financial liabilities		
Trade and other payables	-	2,033,458
Lease liabilities - current	-	44,629
Total current liabilities	-	2,078,087
Lease liabilities - non-current	-	-
Total non-current liabilities	-	-
Total financial liabilities	**-**	**2,078,087**
Net exposure	**11,472,389**	**(1,921,702)**

	Cash and cash equivalents $	Financial assets / liabilities at amortised cost $
As at 30 June 2023		
Financial assets		
Cash and cash equivalents	8,460,074	-
Other receivables and prepayments	-	215,237
Total current assets	8,460,074	215,237
Total financial assets	8,460,074	215,237
Financial liabilities		
Trade and other payables	-	1,559,470
Lease liabilities - current	-	86,933
Total current liabilities	-	1,646,403
Lease liabilities - non-current	-	-
Total non-current liabilities	-	-
Total financial liabilities	-	1,646,403
Net exposure	8,460,074	(1,431,166)

Notes to the Financial Statements

5. OTHER INCOME AND EXPENSES

	Half year ended 31/12/2023 $	Half year ended 31/12/2022 $
Income		
Interest income	106,774	135,912
Other income		
Government grants – R&D Tax Incentive	909,030	1,004,101
Total other income	909,030	1,004,101
Total income	**1,015,804**	1,140,013
Expenses		
Research and development costs		
Laboratory & clinical trial expenses	8,756,459	4,681,286
Regulatory & clinical development consultants	126,811	684,571
Other expenses	69,506	18,549
Total research and development costs	**8,952,776**	5,384,406

Government grants totaling $909,030 was received during the interim period, in connection with R&D expenditure incurred during the prior financial year ended 30 June 2023.

6. CASH AND CASH EQUIVALENTS

	As at 31/12/2023 $	As at 30/06/2023 $
Cash at bank and on hand	2,292,475	1,280,160
Short term deposits	9,179,914	7,179,914
Total cash and cash equivalents	**11,472,389**	8,460,074

7. OTHER RECEIVABLES

	As at 31/12/2023 $	As at 30/06/2023 $
Prepaid insurance	44,400	104,686
Goods and services tax receivable	225,708	129,240
Research and development tax rebate receivable	-	3,883,834
Other receivables	111,990	110,551
Total other receivables and prepayments	**382,098**	4,228,311

None of the other receivables are impaired. Due to their short-term nature, carrying amounts approximate their fair value.

Notes to the Financial Statements

8. PROPERTY, PLANT AND EQUIPMENT

	As at 31/12/2023 $	As at 30/06/2023 $
At cost	69,984	68,484
Accumulated depreciation	(45,014)	(31,208)
Total property, plant and equipment	**24,970**	37,276

Movements during the year

	Computer Equipment $	Total $
Opening balance at 1 July 2022	12,531	12,531
Acquisitions	36,599	36,599
Depreciation	(11,854)	(11,854)
Closing balance at 30 June 2023	37,276	37,276
Opening balance at 1 July 2023	37,276	37,276
Acquisitions	1,500	1,500
Depreciation	(13,806)	(13,806)
Closing balance at 31 December 2023	**24,970**	**24,970**

9. RIGHT-OF-USE ASSET & LEASE LIABILITY

Set out below are the carrying amounts of the Company's assets and lease liabilities recognised in the statement of financial position and the movements during the half year ended 31 December 2023:

	Right-of-use Assets Leased Premises $	Lease Liability Leased Premises $
As at 1 July 2022	156,440	165,270
Depreciation expense	(81,008)	-
Interest expense	-	6,790
Payments	-	(85,127)
As at 30 June 2023	75,432	86,933
As at 1 July 2023	75,432	86,933
Depreciation expense	(40,503)	-
Interest expense (a)	-	1,815
Payments (a)	-	(44,119)
As at 31 December 2023 (b)	**34,929**	**44,629**

(a) The lease payments made during the half year totaled $44,119 comprising $42,304 in principal component and $1,815 in interest expense component.

(b) The total lease liability amounting to $44,629 is current.

Notes to the Financial Statements

9. RIGHT-OF-USE ASSET & LEASE LIABILITY (CONTINUED)

Set out below are the amounts recognised in the statement of comprehensive loss for the half year ended 31 December 2023:

	Half year ended 31/12/2023	Half year ended 31/12/2022
	$	$
Depreciation expense on right-of-use asset	40,504	40,504
Interest expense on lease liabilities	1,815	3,904
Rent expense - short-term leases	-	780
Total amounts recognised in profit or loss	**42,319**	**45,188**

10. INTANGIBLE ASSETS

	As at 31/12/2023	As at 30/06/2023
	$	$
At cost	5,756,743	5,756,743
Accumulated amortisation	(3,506,689)	(3,349,031)
Total intangible assets	**2,250,054**	2,407,712

Movement in Intangible Assets

	Intellectual Property
	$
Opening balance at 1 July 2022	2,720,458
Amortisation expense	(312,746)
Closing balance at 30 June 2023	2,407,712
Opening balance at 1 July 2023	2,407,712
Amortisation expense	(157,658)
Closing balance at 31 December 2023	**2,250,054**

11. TRADE AND OTHER PAYABLES

	As at 31/12/2023	As at 30/06/2023
	$	$
Trade payables	1,880,221	1,101,471
Accruals and other payables	63,667	148,199
Provision for payroll tax	7,239	-
Accrued employee bonuses	-	256,050
Employee tax liabilities	82,331	53,750
Total trade and other payables	**2,033,458**	1,559,470

Trade and other payables are non-interest-bearing liabilities stated at amortised cost and settled within 30 days.

Notes to the Financial Statements

12. CONTRIBUTED EQUITY

(a) Fully paid ordinary shares

	As at 31/12/2023 $	As at 30/06/2023 $
Fully paid ordinary shares	96,177,660	83,652,836
Capital raising costs	(5,394,539)	(4,940,708)
Total contributed equity	**90,783,121**	78,712,128

Movement of fully paid ordinary shares

	Date	Quantity	Unit Price $	Total $
Balance at 1 July 2022		1,795,643,817		76,942,670
Issue of employee loan shares	15/07/2022	250,000	0.066	16,500
Exercise of unlisted options	11/11/2022	1,500,000	0.100	150,000
Exercise of unlisted options	9/12/2022	8,858,333	0.085	752,958
Issue of employee loan shares	20/03/2023	10,000,000	0.085	850,000
Balance at 30 June 2023		1,816,252,150		78,712,128
Issue of rights issue shares	11/09/2023	185,803,027	0.025	4,645,076
Issue of shortfall shares	15/09/2023	214,254,911	0.025	5,356,373
Capital raising costs	-	-	-	(453,831)
Cancellation of loan plan shares	16/10/2023	(2,000,000)	0.000	-
Issue of employee loan shares	8/11/2023	39,750,000	0.022	874,500
Issue of director loan shares	1/12/2023	46,500,000	0.031	1,453,125
Issue of employee loan shares	1/12/2023	6,750,000	0.029	195,750
Balance at 31 December 2023		**2,307,310,088**		**90,783,121**

(b) Reserve shares

Reserves shares ("Loan shares") are ordinary shares that have historically been accounted for as "in-substance options." No loan amount is recognised in the financial statements. As at 31 December 2023, the following reserve shares were on issue.

	Date	Quantity	Unit Price $	Total $
Balance at 1 July 2022		84,762,300)		(6,331,492)
Issue of employee loan shares	15/07/2022	(250,000)	0.066	(16,500)
Issue of employee loan shares	20/03/2023	(10,000,000)	0.085	(850,000)
Balance at 30 June 2023		(95,012,300)		(7,197,992)
Cancellation of Employee Loan Plan Shares	16/10/2023	2,000,000	0.000	-
Issue of Employee Loan Plan Shares	8/11/2023	(39,750,000)	0.022	(874,500)
Issue of director Employee Loan Plan Shares	1/12/2023	(46,500,000)	0.031	(1,453,125)
Issue of Employee Loan Plan Shares	1/12/2023	(6,750,000)	0.029	(195,750)
Balance at 31 December 2023		**(186,012,300)**		**(9,721,367)**

Notes to the Financial Statements

13. RESERVES

Reserves are made up of the option reserve. The option reserve records items recognised as share-based payment (SBP) expenses for employee and Director options. Details of the movement in reserves is shown below.

	As at 31/12/2023 $	As at 30/06/2023 $
Option reserve	11,164,898	10,584,632
Total reserves	**11,164,898**	10,584,632

Movements during the year:

	Half year ended 31/12/2023 $	Year ended 30/06/2023 $
Balance at the beginning of the period	10,584,632	9,067,982
Share-based payment expense on employee options	102	9,867
Share-based payment expense on employee loan shares	467,875	1,130,082
Share-based payment expense on Director loan shares	112,289	376,701
Balance at end of period	**11,164,898**	10,584,632

Total share-based payment expenses recognised during the half year amounted to $580,266.

14. COMMITMENTS AND CONTINGENCIES

The Directors are not aware of any commitments, contingent liabilities or assets that exist at 31 December 2023 (2022: Nil)

15. RELATED PARTY TRANSACTIONS

There were no related party transactions that occurred during the half year.

16. EVENTS OCCURRING AFTER THE REPORTING PERIOD

There are no other matters or circumstances that have arisen since the end of the reporting period which have significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of the Company in subsequent financial years other than those described below:

- On 9 February 2024 the Company issued 18 million loan shares at $0.038 per share to the Chief Financial Officer who commenced employment on 5 February 2024
- On 16 February 2024, 3,000,000 options, exercisable at $0.0375 each and expiring on 15 September 2026, were exercised
- On 16 February 2024, 430,453 options, exercisable at $0.0375 each and expiring on 11 September 2026, were exercised
- On 21 February 2024, 2,418,203 options, exercisable at $0.0375 each and expiring on 15 September 2026, were exercised
- On 21 February 2024, 13,442 options, exercisable at $0.0375 each and expiring on 11 September 2026, were exercised.

Directors' Declaration

In the Directors' opinion:

In accordance with a resolution of the Directors of Actinogen Medical Limited, I state that:

(a) The Financial Statements and Notes set out on pages 11 to 21 are in accordance with the Corporations Act 2001, including:

i. complying with Accounting Standard AASB 134 Interim Financial Reporting, and the Corporations Regulations 2001; and
ii. giving a true and fair view of the Company's financial position as at 31 December 2023 and its performance for the half year ended on that date, and,

(b) Subject to the matter set out in Note 2(b) to the financial statements, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors.

Dr Steven Gourlay
Managing Director
Sydney, New South Wales
26 February 2024

Ernst & Young
11 Mounts Bay Road
Perth WA 6000 Australia
GPO Box M939 Perth WA 6843

Tel: +61 8 9429 2222
Fax: +61 8 9429 2436
ey.com/au

Building a better working world

Independent auditor's review report to the members of Actinogen Medical Limited

Conclusion

We have reviewed the accompanying half-year financial report of Actinogen Medical Limited (the Company), which comprises the statement of financial position as 31 December 2023, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Company does not comply with the *Corporations Act 2001*, including:

a. Giving a true and fair view of the Company's financial position as at 31 December 2023 and of its financial performance for the half-year ended on that date; and

b. Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Material uncertainty related to going concern

We draw attention to Note 2 in the financial report, which describes the events or conditions that raise doubt about the Company's ability to continue as a going concern. These events or conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Directors' responsibilities for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Building a better working world

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2023 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Ernst & Young

Timothy Dachs
Partner
Perth
26 February 2024

Corporate Directory

Board of Directors
Dr Geoffrey Brooke - Non-Executive Chairman
Dr Steven Gourlay - Managing Director & Chief Executive Officer
Dr George Morstyn - Non-Executive Director
Mr Malcolm McComas - Non-Executive Director
Dr Nikki Vasquez - Non-Executive Director

Company Secretary
Mr Peter Webse

Chief Financial Officer
Mr William Souter

Investor Relations
Mr Michael Roberts

Principal Place of Business / Registered Office
Suite 901
109 Pitt St
Sydney NSW 2000

Contact Details
Telephone: 02 8964 7401
info@actinogen.com.au
www.actinogen.com.au
ABN 14 086 778 476

Lawyers
K&L Gates
Level 25 South Tower
525 Collins St
Melbourne VIC 3000

Share Register
Automic Group
Level 5
126 Phillip St
Sydney NSW 2000

Auditors
Ernst & Young
Australia

Securities Exchange
Actinogen Medical Limited shares are listed on the Australian Securities Exchange ('ASX').
ASX Code: ACW